Health Coverage
Analysis: Trump order jeopardizes cost effective, life-changing cure for sickle cell
We are lucky to live in a time when creative scientists are developing life-changing new cures for debilitating genetic diseases. These breakthrough treatments are as important as penicillin or insulin were in their time. Unfortunately, they are also very expensive. To help pay for them, federal Medicaid officials created an opportunity to help states afford…
Read MoreWandering around in OHS’s databases – lots to learn and a surprise
Our state Office of Health Strategy has several impressive portals and dashboards to explore their trove of data and other information. They include healthcare affordability, ED visits, quality ratings, facility plans, self-sufficiency tools, hospital finances, prescription drug costs, and Race, ethnicity and language data. Visitors can sort the data by service, payer, age, gender, and…
Read MoreICER’s 4th annual report finds progress in fair access to prescription drugs
Over the last four years, barriers facing patients getting access to cost effective drugs in commercial plans and the Veteran’s Administration have gotten better, according to ICER’s fourth annual Barriers to Fair Access report. The authors compare plan policies, including cost sharing, clinical eligibility, step therapy and provider restrictions, to independent standards for fair access…
Read MoreMore questions and answers on DSS’s plan for HUSKY maternity bundles
Read the new questions and answers DSS is planning to move Medicaid payments for maternity services from the current fee-for-service arrangement to a per-person bundled payment. They will also expand services to include doula and lactation supports. However, advocates have asked questions and raised concerns about unintended consequences when providers make more money by reducing…
Read MoreMaterials from webinar on improved HUSKY cancer survival in CT without MCOs
Yesterday, Dr. John Cramer described his study published earlier this year describing a significant increase in cancer survival and early detection in Connecticut’s Medicaid program when the Managed Care Organizations left in 2012. Click here for slides and here for a recording of the webinar. The study — Association of Medicaid Privatization With Patient Cancer…
Read MoreAnalysis: DSS Study Suggests MCOs don’t Make Sense for HUSKY
Last Friday, the state released a consultants’ report exploring the Governor’s controversial plan to bring private insurers back to run Medicaid in Connecticut. The report’s authors agree with advocates that there is no evidence that MCOs control costs or improve quality or access to care. They also agree that HUSKY, our state Medicaid program, is…
Read MoreWebinar: Study finds improved early cancer diagnosis and survival after MCOs left HUSKY
Join Rep. Jillian Gilchrest and Sen. Saud Anwar, Co-Chairs of MAPOC, for a webinar December 10th at 2pm with Dr. John Cramer on his study published in JCO Oncology Practice in January. His study found that cancer early detection have increased 4% and survival rates have increased 8% since MCOs left Connecticut Medicaid. There was…
Read MoreAnalysis: How Trump’s Election Could Impact Healthcare in Connecticut
Health policy circles are buzzing with potential policy changes under the second Trump administration. Last time, Trump proposed significant cuts and administrative burdens for Medicaid, which covers 934,043 low-income Connecticut residents. That makes this a very bad time to be considering bringing the failed private Managed Care Organizations (MCOs) back into the program. Other significant…
Read MoreAnalysis: The uninsured are still with us
September used to be a key month for policy wonks. We all eagerly awaited new Census numbers of the uninsured. But since passage of the Affordable Care Act (ACA), there is less attention to the uninsured. There is a sense that we are past the problem of people without coverage. But the latest Census numbers…
Read MoreSix common myths about healthcare and three reasons why people believe them
Healthcare is complicated, people are easily confused, and there are powerful motivations to believe the many misconceptions. I was reminded of this at the last meeting of the industry-led group that is steering the state’s efforts to control healthcare costs. But the problem isn’t limited to industry representatives. Read more
Read More